Figures computed from official regulatory filings — .
Ownershipinsiders 43.53% · institutions 0% · short 2.5% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Oncotelic Therapeutics, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment of orphan oncology indications in the United States. The company develops antisense and small molecule injectable drugs for the treatment of cancer. It is also developing OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer, melanoma, and glioblastoma, as well as for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. In addition, the company develops CA4P for the treatment of advanced metastatic melanoma; AL-101, an intranasal drug and delivery system for intra-nasal apomorphine for the treatment of parkinson's disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of support technologies, as well as nanoparticle products for the treatment of various cancers. The company is based in Agoura Hills, California.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
139 buys1 sell— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Fein Seymour Howard | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| KING STEVEN W | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Trieu Vuongtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Shah Amit B. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| MAIDA ANTHONY E IIItrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Saund Saran | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Trieu Vuongtrack record | Buy | $10.3K | conv 40 | SEC |
| Trieu Vuongtrack record | Buy | $2.9K | conv 28 | SEC |
| Trieu Vuongtrack record | Buy | $3.4K | conv 28 | SEC |
| Trieu Vuongtrack record | Buy | $5.2K | conv 28 | SEC |
| Shah Amit B. | Buy | $1K | conv 43First in 12mo | SEC |
| Trieu Vuongtrack record | Buy | $4.3K | conv 32 | SEC |
| Trieu Vuongtrack record | Buy | $10.7K | conv 41 | SEC |
| Trieu Vuongtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Trieu Vuongtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Trieu Vuongtrack record | Buy | $0 | conv 28 | SEC |
| Trieu Vuongtrack record | Buy | $947.4 | conv 33 | SEC |
| Trieu Vuongtrack record | Buy | $1K | conv 28 | SEC |
| Trieu Vuongtrack record | Buy | $1.9K | conv 28 | SEC |
| Trieu Vuongtrack record | Buy | $3K | conv 28 | SEC |
| Trieu Vuongtrack record | Buy | $5.5K | conv 30 | SEC |
| Trieu Vuongtrack record | Buy | $9K | conv 31 | SEC |
| Trieu Vuongtrack record | Buy | $10K | conv 51First in 12mo | SEC |
| Trieu Vuongtrack record | Buy | $2.3K | conv 40 | SEC |
| Trieu Vuongtrack record | Buy | $8.5K | conv 40 | SEC |